-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Downgrades Evolent Health to Hold, Maintains Price Target to $7

Benzinga·06/30/2026 13:51:06
Listen to the news
Truist Securities analyst Jailendra Singh downgrades Evolent Health (NYSE:EVH) from Buy to Hold and maintains the price target from $7 to $7.